Bioventus Inc.

NasdaqGS:BVS Stock Report

Market Cap: US$698.1m

Bioventus Future Growth

Future criteria checks 3/6

Bioventus is forecast to grow earnings and revenue by 110.7% and 2.3% per annum respectively. EPS is expected to grow by 116.1% per annum. Return on equity is forecast to be 14.3% in 3 years.

Key information

110.7%

Earnings growth rate

116.1%

EPS growth rate

Medical Equipment earnings growth12.9%
Revenue growth rate2.3%
Future return on equity14.3%
Analyst coverage

Low

Last updated31 Jan 2025

Recent future growth updates

Recent updates

Bioventus: Amply Rewarded For Recent Progress

Jan 05

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Aug 12

Bioventus: Bullish On Path To Profitability

Jan 24

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

Sep 08

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Aug 11

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Aug 03

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Jun 14

Bioventus: Thoughts After An Active First Year

Mar 29

Earnings and Revenue Growth Forecasts

NasdaqGS:BVS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265911882743
12/31/2025555175653
12/31/2024565-482483
9/28/2024555-392830N/A
6/29/2024537-42811N/A
3/30/2024523-2227N/A
12/31/2023512-97815N/A
9/30/2023503-104010N/A
7/1/2023511-169818N/A
4/1/2023514-173-110N/A
12/31/2022512-104-24-14N/A
10/1/2022517-91-15-6N/A
7/2/2022497-19-46N/A
4/2/2022466-161120N/A
12/31/2021431-5923N/A
10/2/2021399-32935N/A
7/3/202137664046N/A
4/3/202132443136N/A
12/31/2020321165572N/A
9/26/2020320167167N/A
6/27/2020316126258N/A
3/28/2020339155554N/A
12/31/201934093841N/A
12/31/2018319-14345N/A
4/2/2016266-23N/A25N/A
12/31/2015254-38N/A19N/A
12/31/2014243-17N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BVS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: BVS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BVS is expected to become profitable in the next 3 years.

Revenue vs Market: BVS's revenue (2.3% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: BVS's revenue (2.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BVS's Return on Equity is forecast to be low in 3 years time (14.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 04:47
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/28
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioventus Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Caitlin CroninCanaccord Genuity
Kyle RoseCanaccord Genuity